Net earnings and diluted earnings per share for the first quarter of 2017 were
“
The Company is now including the estimated impact of the Actelion transaction in its financial guidance. As such, the Company increased its sales guidance for the full-year 2017 to
Worldwide Consumer sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by LISTERINE® oral care products, baby care products, and wound care products, partially offset by growth in over-the-counter products, including domestic TYLENOL® analgesics.
Worldwide Pharmaceutical sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by new products and the strength of core products. Strong growth in new products include DARZALEX® (daratumumab), for the treatment of patients with multiple myeloma and IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA® (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, and INVEGA® SUSTENNA®/XEPLION®/TRINZA® (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. Sales growth was negatively impacted by a positive adjustment of rebate accruals in the first quarter of 2016, which did not occur to the same degree in the first quarter of 2017.
During the quarter, the Company announced a definitive agreement to acquire Actelion Ltd., a leading biopharmaceutical company, for approximately
Also in the quarter, the Committee for Medicinal Products for Human Use of the
In April, subsequent to the quarter, a marketing authorization application was submitted to the
Worldwide Medical Devices sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business; ACUVUE® contact lenses in the Vision Care business and endocutters in the Advanced Surgery business, partially offset by declines in the Diabetes Care business.
During the quarter, the company completed the acquisition of
Additionally, the acquisitions of
In April, subsequent to the quarter, the acquisition of
About
Caring for the world, one person at a time, inspires and unites the people of
* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
|
||||||||||
Supplementary Sales Data |
||||||||||
(Unaudited; Dollars in Millions) |
FIRST QUARTER |
|||||||||
Percent Change |
||||||||||
2017 |
2016 |
Total |
Operations |
Currency |
||||||
Sales to customers by |
||||||||||
segment of business |
||||||||||
Consumer |
||||||||||
|
$ 1,414 |
1,358 |
4.1 |
% |
4.1 |
– |
||||
International |
1,814 |
1,837 |
(1.3) |
(1.6) |
0.3 |
|||||
3,228 |
3,195 |
1.0 |
0.8 |
0.2 |
||||||
Pharmaceutical |
||||||||||
|
4,872 |
4,937 |
(1.3) |
(1.3) |
– |
|||||
International |
3,373 |
3,241 |
4.1 |
5.6 |
(1.5) |
|||||
8,245 |
8,178 |
0.8 |
1.4 |
(0.6) |
||||||
Medical Devices |
||||||||||
|
3,092 |
3,026 |
2.2 |
2.2 |
– |
|||||
International |
3,201 |
3,083 |
3.8 |
4.7 |
(0.9) |
|||||
6,293 |
6,109 |
3.0 |
3.4 |
(0.4) |
||||||
|
9,378 |
9,321 |
0.6 |
0.6 |
– |
|||||
International |
8,388 |
8,161 |
2.8 |
3.6 |
(0.8) |
|||||
Worldwide |
|
17,482 |
1.6 |
% |
2.0 |
(0.4) |
|
||||||||||
Supplementary Sales Data |
||||||||||
(Unaudited; Dollars in Millions) |
FIRST QUARTER |
|||||||||
Percent Change |
||||||||||
2017 |
2016 |
Total |
Operations |
Currency |
||||||
Sales to customers by |
||||||||||
geographic area |
||||||||||
|
$ 9,378 |
9,321 |
0.6 |
% |
0.6 |
– |
||||
|
3,858 |
3,847 |
0.3 |
4.2 |
(3.9) |
|||||
Western Hemisphere excluding |
1,454 |
1,331 |
9.2 |
2.5 |
6.7 |
|||||
|
3,076 |
2,983 |
3.1 |
3.4 |
(0.3) |
|||||
International |
8,388 |
8,161 |
2.8 |
3.6 |
(0.8) |
|||||
Worldwide |
|
17,482 |
1.6 |
% |
2.0 |
(0.4) |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
FIRST QUARTER |
||||||||
2017 |
2016 |
Percent |
|||||||
Percent |
Percent |
Increase |
|||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) |
|||||
Sales to customers |
$ 17,766 |
100.0 |
$ 17,482 |
100.0 |
1.6 |
||||
Cost of products sold |
5,386 |
30.3 |
5,329 |
30.5 |
1.1 |
||||
Selling, marketing and administrative expenses |
4,737 |
26.6 |
4,688 |
26.8 |
1.0 |
||||
Research and development expense |
2,060 |
11.6 |
2,013 |
11.5 |
2.3 |
||||
Interest (income) expense, net |
83 |
0.5 |
77 |
0.4 |
|||||
Other (income) expense, net |
(160) |
(0.9) |
(39) |
(0.2) |
|||||
Restructuring |
85 |
0.5 |
120 |
0.7 |
|||||
Earnings before provision for taxes on income |
5,575 |
31.4 |
5,294 |
30.3 |
5.3 |
||||
Provision for taxes on income |
1,153 |
6.5 |
837 |
4.8 |
37.8 |
||||
Net earnings |
4,422 |
24.9 |
4,457 |
25.5 |
(0.8) |
||||
Net earnings per share (Diluted) |
$ 1.61 |
$ 1.59 |
1.3 |
||||||
Average shares outstanding (Diluted) |
2,754.5 |
2,803.8 |
|||||||
Effective tax rate |
20.7 |
% |
15.8 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
$ 6,103 |
34.4 |
$ 5,801 |
33.2 |
5.2 |
||||
Net earnings |
$ 5,038 |
28.4 |
$ 4,854 |
27.8 |
3.8 |
||||
Net earnings per share (Diluted) |
$ 1.83 |
$ 1.73 |
5.8 |
||||||
Effective tax rate |
17.5 |
% |
16.3 |
% |
|||||
(1)See Reconciliation of Non-GAAP Financial Measures. |
|
|||||||
Reconciliation of Non-GAAP Financial Measures |
|||||||
First Quarter |
% Incr. / |
||||||
(Dollars in Millions Except Per Share Data) |
2017 |
2016 |
(Decr.) |
||||
Earnings before provision for taxes on income – as reported |
$ 5,575 |
5,294 |
5.3 |
% |
|||
Intangible asset amortization expense |
329 |
282 |
|||||
Restructuring/Other (1) |
161 |
137 |
|||||
Litigation expense, net |
– |
66 |
|||||
AMO acquisition related cost |
38 |
– |
|||||
Other |
– |
22 |
|||||
Earnings before provision for taxes on income – as adjusted |
$ 6,103 |
5,801 |
5.2 |
% |
|||
Net Earnings – as reported |
$ 4,422 |
4,457 |
(0.8) |
% |
|||
Intangible asset amortization expense |
244 |
205 |
|||||
Restructuring/Other |
121 |
120 |
|||||
Litigation expense, net |
– |
56 |
|||||
AMO acquisition related cost |
251 |
– |
|||||
Other |
– |
16 |
|||||
Net Earnings – as adjusted |
$ 5,038 |
4,854 |
3.8 |
% |
|||
Diluted Net Earnings per share – as reported |
$ 1.61 |
1.59 |
1.3 |
% |
|||
Intangible asset amortization expense |
0.09 |
0.07 |
|||||
Restructuring/Other |
0.04 |
0.04 |
|||||
Litigation expense, net |
– |
0.02 |
|||||
AMO acquisition related cost |
0.09 |
– |
|||||
Other |
– |
0.01 |
|||||
Diluted Net Earnings per share – as adjusted |
$ 1.83 |
1.73 |
5.8 |
% |
|||
Operational Diluted Net Earnings per share – as adjusted at 2015 foreign currency exchange rates |
1.77 |
||||||
Impact of currency at 2016 foreign currency exchange rates |
0.03 |
(0.04) |
|||||
Operational Diluted Net Earnings per share – as adjusted at 2016 foreign currency exchange rates |
$ 1.86 |
1.73 |
7.5 |
% |
|||
(1) Includes |
|||||||
|
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures |
||||||||
FIRST QUARTER 2017 ACTUAL vs. 2016 ACTUAL |
||||||||
Segments |
||||||||
Consumer |
Pharmaceutical |
Medical Devices |
Total |
|||||
Operational %(1) |
||||||||
WW As Reported: |
0.8% |
1.4% |
3.4% |
2.0% |
||||
U.S. |
4.1% |
(1.3)% |
2.2% |
0.6% |
||||
International |
(1.6)% |
5.6% |
4.7% |
3.6% |
||||
Beauty |
||||||||
|
(3.0) |
(0.6) |
||||||
U.S. |
(6.3) |
(0.9) |
||||||
International |
(0.7) |
(0.1) |
||||||
Other Neuroscience |
||||||||
Controlled Substance Raw Material and API Business |
0.8 |
0.4 |
||||||
U.S. |
0.9 |
0.5 |
||||||
International |
0.5 |
0.2 |
||||||
Diagnostics |
||||||||
|
0.5 |
0.2 |
||||||
U.S. |
0.0 |
0.0 |
||||||
International |
1.0 |
0.4 |
||||||
Vision Care |
||||||||
|
(2.0) |
(0.7) |
||||||
U.S. |
(1.7) |
(0.6) |
||||||
International |
(2.3) |
(0.9) |
||||||
All Other Acquisitions and Divestitures |
(0.1) |
(0.2) |
(0.1) |
|||||
U.S. |
(0.7) |
(0.7) |
(0.3) |
|||||
International |
0.4 |
0.3 |
0.2 |
|||||
WW Ops excluding Acquisitions and Divestitures |
(2.3)% |
2.2% |
1.7% |
1.2% |
||||
U.S. |
(2.9)% |
(0.4)% |
(0.2)% |
(0.7)% |
||||
International |
(1.9)% |
6.1% |
3.7% |
3.4% |
||||
(1)Operational growth excludes the effect of translational currency |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||
FIRST QUARTER |
|||||||
% Change |
|||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
|||
CONSUMER SEGMENT (2) (3) |
|||||||
|
|||||||
US |
$ 113 |
121 |
-6.6% |
-6.6% |
– |
||
Intl |
342 |
362 |
-5.5% |
-6.1% |
0.6% |
||
WW |
455 |
483 |
-5.8% |
-6.3% |
0.5% |
||
BEAUTY |
|||||||
US |
567 |
484 |
17.1% |
17.1% |
– |
||
Intl |
414 |
395 |
4.8% |
5.0% |
-0.2% |
||
WW |
981 |
879 |
11.6% |
11.7% |
-0.1% |
||
|
|||||||
US |
156 |
170 |
-8.2% |
-8.2% |
– |
||
Intl |
206 |
215 |
-4.2% |
-4.5% |
0.3% |
||
WW |
362 |
385 |
-6.0% |
-6.2% |
0.2% |
||
OTC |
|||||||
US |
477 |
466 |
2.4% |
2.4% |
– |
||
Intl |
536 |
533 |
0.6% |
0.7% |
-0.1% |
||
WW |
1,013 |
999 |
1.4% |
1.5% |
-0.1% |
||
WOMEN’S HEALTH |
|||||||
US |
3 |
6 |
-50.0% |
-50.0% |
– |
||
Intl |
239 |
245 |
-2.4% |
-4.2% |
1.8% |
||
WW |
242 |
251 |
-3.6% |
-5.3% |
1.7% |
||
WOUND CARE / OTHER |
|||||||
US |
98 |
111 |
-11.7% |
-11.7% |
– |
||
Intl |
77 |
87 |
-11.5% |
-12.3% |
0.8% |
||
WW |
175 |
198 |
-11.6% |
-11.9% |
0.3% |
||
TOTAL CONSUMER |
|||||||
US |
1,414 |
1,358 |
4.1% |
4.1% |
– |
||
Intl |
1,814 |
1,837 |
-1.3% |
-1.6% |
0.3% |
||
WW |
$ 3,228 |
3,195 |
1.0% |
0.8% |
0.2% |
||
See footnotes at end of schedule |
|||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||
FIRST QUARTER |
|||||||
% Change |
|||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
|||
PHARMACEUTICAL SEGMENT (2) (3) |
|||||||
IMMUNOLOGY |
|||||||
US |
$ 2,123 |
2,171 |
-2.2% |
-2.2% |
– |
||
Intl |
807 |
739 |
9.2% |
9.0% |
0.2% |
||
WW |
2,930 |
2,910 |
0.7% |
0.6% |
0.1% |
||
REMICADE |
|||||||
US |
1,182 |
1,211 |
-2.4% |
-2.4% |
– |
||
US Exports (4) |
165 |
233 |
-29.2% |
-29.2% |
– |
||
Intl |
325 |
335 |
-3.0% |
-4.8% |
1.8% |
||
WW |
1,672 |
1,779 |
-6.0% |
-6.3% |
0.3% |
||
SIMPONI / SIMPONI ARIA |
|||||||
US |
229 |
216 |
6.0% |
6.0% |
– |
||
Intl |
199 |
174 |
14.4% |
13.4% |
1.0% |
||
WW |
428 |
390 |
9.7% |
9.2% |
0.5% |
||
STELARA |
|||||||
US |
547 |
511 |
7.0% |
7.0% |
– |
||
Intl |
276 |
224 |
23.2% |
26.1% |
-2.9% |
||
WW |
823 |
735 |
12.0% |
12.9% |
-0.9% |
||
OTHER IMMUNOLOGY |
|||||||
US |
– |
– |
– |
– |
– |
||
Intl |
7 |
6 |
16.7% |
12.1% |
4.6% |
||
WW |
7 |
6 |
16.7% |
12.1% |
4.6% |
||
INFECTIOUS DISEASES |
|||||||
US |
326 |
358 |
-8.9% |
-8.9% |
– |
||
Intl |
423 |
418 |
1.2% |
2.8% |
-1.6% |
||
WW |
749 |
776 |
-3.5% |
-2.6% |
-0.9% |
||
EDURANT / RILPIVIRINE |
|||||||
US |
12 |
11 |
9.1% |
9.1% |
– |
||
Intl |
137 |
108 |
26.9% |
30.4% |
-3.5% |
||
WW |
149 |
119 |
25.2% |
28.3% |
-3.1% |
||
PREZISTA / PREZCOBIX / REZOLSTA |
|||||||
US |
259 |
277 |
-6.5% |
-6.5% |
– |
||
Intl |
171 |
175 |
-2.3% |
0.2% |
-2.5% |
||
WW |
430 |
452 |
-4.9% |
-3.9% |
-1.0% |
||
OTHER INFECTIOUS DISEASES |
|||||||
US |
55 |
70 |
-21.4% |
-21.4% |
– |
||
Intl |
115 |
135 |
-14.8% |
-15.9% |
1.1% |
||
WW |
170 |
205 |
-17.1% |
-17.8% |
0.7% |
||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||
FIRST QUARTER |
|||||||
% Change |
|||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
|||
NEUROSCIENCE |
|||||||
US |
664 |
680 |
-2.4% |
-2.4% |
– |
||
Intl |
833 |
869 |
-4.1% |
-2.9% |
-1.2% |
||
WW |
1,497 |
1,549 |
-3.4% |
-2.7% |
-0.7% |
||
CONCERTA / METHYLPHENIDATE |
|||||||
US |
108 |
134 |
-19.4% |
-19.4% |
– |
||
Intl |
101 |
97 |
4.1% |
4.2% |
-0.1% |
||
WW |
209 |
231 |
-9.5% |
-9.5% |
0.0% |
||
INVEGA SUSTENNA / XEPLION / TRINZA |
|||||||
US |
372 |
305 |
22.0% |
22.0% |
– |
||
Intl |
232 |
208 |
11.5% |
14.3% |
-2.8% |
||
WW |
604 |
513 |
17.7% |
18.8% |
-1.1% |
||
RISPERDAL CONSTA |
|||||||
US |
95 |
95 |
0.0% |
0.0% |
– |
||
Intl |
112 |
136 |
-17.6% |
-15.7% |
-1.9% |
||
WW |
207 |
231 |
-10.4% |
-9.3% |
-1.1% |
||
OTHER NEUROSCIENCE |
|||||||
US |
89 |
146 |
-39.0% |
-39.0% |
– |
||
Intl |
388 |
428 |
-9.3% |
-8.9% |
-0.4% |
||
WW |
477 |
574 |
-16.9% |
-16.6% |
-0.3% |
||
ONCOLOGY |
|||||||
US |
664 |
549 |
20.9% |
20.9% |
– |
||
Intl |
930 |
805 |
15.5% |
18.3% |
-2.8% |
||
WW |
1,594 |
1,354 |
17.7% |
19.3% |
-1.6% |
||
DARZALEX |
|||||||
US |
201 |
101 |
99.0% |
99.0% |
– |
||
Intl |
54 |
– |
* |
* |
0.0% |
||
WW |
255 |
101 |
* |
* |
0.0% |
||
IMBRUVICA |
|||||||
US |
190 |
132 |
43.9% |
43.9% |
– |
||
Intl |
219 |
129 |
69.8% |
73.7% |
-3.9% |
||
WW |
409 |
261 |
56.7% |
58.6% |
-1.9% |
||
VELCADE |
|||||||
US |
– |
– |
– |
– |
– |
||
Intl |
280 |
304 |
-7.9% |
-5.0% |
-2.9% |
||
WW |
280 |
304 |
-7.9% |
-5.0% |
-2.9% |
||
ZYTIGA |
|||||||
US |
233 |
272 |
-14.3% |
-14.3% |
– |
||
Intl |
290 |
286 |
1.4% |
2.7% |
-1.3% |
||
WW |
523 |
558 |
-6.3% |
-5.6% |
-0.7% |
||
OTHER ONCOLOGY |
|||||||
US |
40 |
44 |
-9.1% |
-9.1% |
– |
||
Intl |
87 |
86 |
1.2% |
4.1% |
-2.9% |
||
WW |
127 |
130 |
-2.3% |
-0.4% |
-1.9% |
||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||
FIRST QUARTER |
|||||||
% Change |
|||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
|||
CARDIOVASCULAR / METABOLISM / OTHER |
|||||||
US |
1,095 |
1,179 |
-7.1% |
-7.1% |
– |
||
Intl |
380 |
410 |
-7.3% |
-4.5% |
-2.8% |
||
WW |
1,475 |
1,589 |
-7.2% |
-6.5% |
-0.7% |
||
XARELTO |
|||||||
US |
513 |
567 |
-9.5% |
-9.5% |
– |
||
Intl |
– |
– |
– |
– |
– |
||
WW |
513 |
567 |
-9.5% |
-9.5% |
– |
||
INVOKANA / INVOKAMET |
|||||||
US |
247 |
297 |
-16.8% |
-16.8% |
– |
||
Intl |
37 |
28 |
32.1% |
32.8% |
-0.7% |
||
WW |
284 |
325 |
-12.6% |
-12.5% |
-0.1% |
||
PROCRIT / EPREX |
|||||||
US |
169 |
183 |
-7.7% |
-7.7% |
– |
||
Intl |
78 |
91 |
-14.3% |
-13.1% |
-1.2% |
||
WW |
247 |
274 |
-9.9% |
-9.5% |
-0.4% |
||
OTHER |
|||||||
US |
166 |
132 |
25.8% |
25.8% |
– |
||
Intl |
265 |
291 |
-8.9% |
-5.4% |
-3.5% |
||
WW |
431 |
423 |
1.9% |
4.3% |
-2.4% |
||
TOTAL PHARMACEUTICAL |
|||||||
US |
4,872 |
4,937 |
-1.3% |
-1.3% |
– |
||
Intl |
3,373 |
3,241 |
4.1% |
5.6% |
-1.5% |
||
WW |
$ 8,245 |
8,178 |
0.8% |
1.4% |
-0.6% |
||
See footnotes at end of schedule |
|||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||
FIRST QUARTER |
|||||||
% Change |
|||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
|||
MEDICAL DEVICES SEGMENT (2) |
|||||||
CARDIOVASCULAR |
|||||||
US |
$ 259 |
231 |
12.1% |
12.1% |
– |
||
Intl |
240 |
212 |
13.2% |
14.2% |
-1.0% |
||
WW |
499 |
443 |
12.6% |
13.1% |
-0.5% |
||
DIABETES CARE |
|||||||
US |
154 |
180 |
-14.4% |
-14.4% |
– |
||
Intl |
245 |
249 |
-1.6% |
-0.8% |
-0.8% |
||
WW |
399 |
429 |
-7.0% |
-6.5% |
-0.5% |
||
DIAGNOSTICS |
|||||||
US |
– |
– |
– |
– |
– |
||
Intl |
1 |
28 |
** |
** |
** |
||
WW |
1 |
28 |
** |
** |
** |
||
ORTHOPAEDICS |
|||||||
US |
1,379 |
1,392 |
-0.9% |
-0.9% |
– |
||
Intl |
946 |
949 |
-0.3% |
1.0% |
-1.3% |
||
WW |
2,325 |
2,341 |
-0.7% |
-0.2% |
-0.5% |
||
HIPS |
|||||||
US |
209 |
203 |
3.0% |
3.0% |
– |
||
Intl |
143 |
139 |
2.9% |
4.5% |
-1.6% |
||
WW |
352 |
342 |
2.9% |
3.5% |
-0.6% |
||
KNEES |
|||||||
US |
246 |
244 |
0.8% |
0.8% |
– |
||
Intl |
152 |
145 |
4.8% |
7.0% |
-2.2% |
||
WW |
398 |
389 |
2.3% |
3.1% |
-0.8% |
||
TRAUMA |
|||||||
US |
391 |
381 |
2.6% |
2.6% |
– |
||
Intl |
251 |
261 |
-3.8% |
-3.1% |
-0.7% |
||
WW |
642 |
642 |
0.0% |
0.3% |
-0.3% |
||
SPINE & OTHER |
|||||||
US |
533 |
564 |
-5.5% |
-5.5% |
– |
||
Intl |
400 |
404 |
-1.0% |
0.3% |
-1.3% |
||
WW |
933 |
968 |
-3.6% |
-3.1% |
-0.5% |
||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||
FIRST QUARTER |
|||||||
% Change |
|||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
|||
SURGERY |
|||||||
US |
995 |
981 |
1.4% |
1.4% |
– |
||
Intl |
1,276 |
1,247 |
2.3% |
3.3% |
-1.0% |
||
WW |
2,271 |
2,228 |
1.9% |
2.5% |
-0.6% |
||
ADVANCED |
|||||||
US |
392 |
352 |
11.4% |
11.4% |
– |
||
Intl |
485 |
464 |
4.5% |
5.9% |
-1.4% |
||
WW |
877 |
816 |
7.5% |
8.3% |
-0.8% |
||
GENERAL |
|||||||
US |
423 |
419 |
1.0% |
1.0% |
– |
||
Intl |
651 |
651 |
0.0% |
1.2% |
-1.2% |
||
WW |
1,074 |
1,070 |
0.4% |
1.1% |
-0.7% |
||
SPECIALTY |
|||||||
US |
180 |
210 |
-14.3% |
-14.3% |
– |
||
Intl |
140 |
132 |
6.1% |
4.8% |
1.3% |
||
WW |
320 |
342 |
-6.4% |
-6.9% |
0.5% |
||
VISION CARE |
|||||||
US |
305 |
242 |
26.0% |
26.0% |
– |
||
Intl |
493 |
398 |
23.9% |
23.6% |
0.3% |
||
WW |
798 |
640 |
24.7% |
24.5% |
0.2% |
||
CONTACT LENSES / OTHER |
|||||||
US |
256 |
242 |
5.8% |
5.8% |
– |
||
Intl |
427 |
398 |
7.3% |
7.0% |
0.3% |
||
WW |
683 |
640 |
6.7% |
6.5% |
0.2% |
||
SURGICAL |
|||||||
US |
49 |
– |
** |
** |
– |
||
Intl |
66 |
– |
** |
** |
0.0% |
||
WW |
115 |
– |
** |
** |
0.0% |
||
TOTAL MEDICAL DEVICES |
|||||||
US |
3,092 |
3,026 |
2.2% |
2.2% |
– |
||
Intl |
3,201 |
3,083 |
3.8% |
4.7% |
-0.9% |
||
WW |
$ 6,293 |
6,109 |
3.0% |
3.4% |
-0.4% |
||
* Percentage greater than 100% |
|||||||
** Not meaningful |
|||||||
(1) Operational growth excludes the effect of translational currency |
|||||||
(2) Unaudited |
|||||||
(3) Prior year amounts have been reclassified to conform to current year product disclosure |
|||||||
(4) Reported as |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson–johnson-reports-2017-first-quarter-results-300440779.html
SOURCE
Research Reports Coverage on Generic Drugs Stocks — Innocoll, Catalyst Pharma, Galectin Therapeutics, and Tetraphase Pharma
Comerica Reports First Quarter 2017 Earnings
More Articles